Scalable Production Process for Model Protein-loaded PLGA Nanoparticles: Release Properties, Trafficking and Biocompatibility

Alsaab Jani^*
*Correspondence: Alsaab Jani, Department of Physics and Astronomy, University of Florence, Via G. Sansone 1, 50019 Sesto Fiorentino, Italy, Email:

Introduction

Protein-based therapeutics have shown tremendous promise in the treatment of a variety of diseases, such as cancer, autoimmune disorders and genetic conditions. Despite their therapeutic potential, proteins face several challenges that hinder their clinical efficacy. These challenges include poor stability, rapid enzymatic degradation and fast clearance from the body. Nanotechnology, particularly the use of nanoparticles, has emerged as a promising approach to address these challenges by enhancing the bioavailability, stability and controlled release of protein therapeutics. Poly(Lactic-Co-Glycolic Acid) (PLGA) nanoparticles have garnered significant interest in this field due to their biocompatibility, biodegradability and ability to encapsulate a wide range of active ingredients, including proteins. This paper explores the scalable production processes for protein-loaded PLGA nanoparticles, with a focus on their release properties, trafficking mechanisms and biocompatibility.

Description

The development of drug delivery systems that can enhance the stability, bioavailability and therapeutic efficacy of protein-based drugs has been a critical area of research. Proteins, unlike small-molecule drugs, have complex structures that are susceptible to degradation under various physiological conditions, which complicates their administration and limits their therapeutic potential. Additionally, proteins typically require frequent dosing and face issues such as rapid clearance and poor penetration into target tissues. PLGA is a biodegradable and biocompatible copolymer made from lactic acid and glycolic acid. The unique properties of PLGA, such as its biodegradability, which occurs via hydrolytic cleavage of the ester bonds in the polymer backbone and its ability to form stable nanoparticle systems, make it an excellent candidate for protein delivery. Upon administration, PLGA nanoparticles degrade in the body, releasing their cargo over time without causing significant toxicity or immune responses. PLGA nanoparticles can be designed to encapsulate a wide range of proteins, including therapeutic antibodies, enzymes, hormones and vaccines. The success of these nanoparticle systems depends on the careful optimization of formulation parameters such as particle size, surface charge and drugloading efficiency. PLGA nanoparticles have emerged as one of the most promising carriers for protein delivery. These nanoparticles can encapsulate proteins in their core, protecting them from enzymatic degradation and offering sustained and controlled release over time. The ability to modulate the release profile of the protein and the biocompatibility of PLGA makes it an attractive choice for the development of efficient and scalable protein delivery systems. Despite their potential, the large-scale production of protein-loaded PLGA nanoparticles remains a significant challenge. Achieving scalable production requires not only efficient encapsulation of the protein but also the preservation of the proteinâ??s activity and the development of a reproducible process. In this context, understanding the release properties, trafficking behavior and biocompatibility of these nanoparticles is essential for their successful translation to clinical use [1,2].

Conclusion

Protein-loaded PLGA nanoparticles represent a promising platform for the controlled delivery of protein therapeutics. By encapsulating proteins within PLGA nanoparticles, their stability, bioavailability and release profile can be significantly improved. The scalable production of these nanoparticles is critical for their widespread clinical use and several methods, including solvent evaporation, nanoprecipitation, coacervation and spray-drying, can be employed to achieve this goal. The release properties of protein-loaded PLGA nanoparticles can be precisely controlled through adjustments to the polymer composition and nanoparticle size. Additionally, surface modifications can enhance the targeting efficiency and biocompatibility of the nanoparticles. By optimizing these factors, it is possible to create a highly effective and biocompatible drug delivery system that can improve the therapeutic outcomes of protein-based drugs.

References

1. Primavessy, Daniel, Nazende Günday Türeli and Marc Schneider. "Influence of different stabilizers on the encapsulation of desmopressin acetate into PLGA nanoparticles." Eur J Pharm Biopharm. 118 (2017): 48-55.

Google Scholar, Crossref, Indexed at

2. Rietscher, René, Justyna A. Czaplewska, Tobias C. Majdanski and Michael Gottschaldt, et al. "Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release." Int J Pharm 500 (2016): 187-195.

Google Scholar, Crossref, Indexed at